Can we leverage Single Arm Trials to accelerate Market Access and how do we achieve this in different markets?

With an increase in products pursuing rapid or lean clinical validation via Single Arm Trials (SATs) and favourable regulatory environments that enable this, our client sought to map ex-US regulatory and reimbursement pathways for assets with SATs, and identify creative tactics used to ensure and accelerate access, including stakeholder engagement.

Eradigm’s comprehensive mapping of key access considerations, impact of SATs on access outcomes and identification of market-specific tactics enabled our client to pressure test their hypotheses, identify unique opportunities and tactics to accelerate access with their pipeline and engage with cross-functional teams (R&D, medical affairs, access) to shape long-term strategy.